Erratum to: No more pain upon Gq-protein-coupled receptor activation: Role of endocannabinoids. [Eur. J. Neurosci., (2014), 39, 467-484. doi: 10.1111/ejn.12475];No more pain upon G q -protein-coupled receptor activation: Role of endocannabinoids

European Journal of Neuroscience

Volumn 39, Issue 3, 2014, Pages 467-484

  Hu, Sherry Shu Jung ^a   Ho, Yu Cheng ^b   Chiou, Lih Chu ^b,c  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

Endocannabinoids; Metabotropic glutamate receptors; Neuropeptides; Pain; Periaqueductal gray

Indexed keywords

2 ARACHIDONOYLGLYCEROL; 4 AMINOBUTYRIC ACID RECEPTOR; ACYLGLYCEROL LIPASE; ANANDAMIDE; CANNABINOID; CANNABINOID 1 RECEPTOR; CANNABINOID 1 RECEPTOR ANTAGONIST; CANNABINOID 2 RECEPTOR; CANNABINOID 2 RECEPTOR ANTAGONIST; CANNABINOID RECEPTOR ANTAGONIST; CAPSAICIN; CHOLECYSTOKININ A RECEPTOR; ENDOCANNABINOID; ENZYME INHIBITOR; FATTY ACID AMIDASE; FATTY ACID AMIDASE INHIBITOR; G PROTEIN COUPLED RECEPTOR; LIPOXIN A; METABOTROPIC RECEPTOR 5; MONOACYLGLYCEROL LIPASE INHIBITOR; MUSCARINIC M1 RECEPTOR; MUSCARINIC M3 RECEPTOR; NEUROKININ 1 RECEPTOR; NEUROPEPTIDE; NEUROTENSIN; OREXIN 1 RECEPTOR; SUBSTANCE P; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANILLOID RECEPTOR; VANILLOID RECEPTOR 1; CANNABINOID RECEPTOR; CANNABINOID RECEPTOR AGONIST;

ANALGESIA; ANALGESIC ACTIVITY; ANTINOCICEPTION; ARTICLE; BIOSYNTHESIS; CHRONIC PAIN; DRUG MECHANISM; ENZYME DEGRADATION; ENZYME INHIBITION; HUMAN; KNOCKOUT MOUSE; NONHUMAN; PAIN; PERIAQUEDUCTAL GRAY MATTER; PRIORITY JOURNAL; REGULATORY MECHANISM; SPINAL CORD DORSAL HORN; ANIMAL; METABOLISM; METABOTROPIC GLUTAMATE RECEPTORS; REVIEW; SYNTHESIS;

ENDOCANNABINOIDS; METABOTROPIC GLUTAMATE RECEPTORS; NEUROPEPTIDES; PAIN; PERIAQUEDUCTAL GRAY;

ANIMALS; CANNABINOID RECEPTOR AGONISTS; ENDOCANNABINOIDS; HUMANS; PAIN; RECEPTORS, CANNABINOID;

EID: 84893373739     PISSN: 0953816X     EISSN: 14609568     Source Type: Journal    
DOI: 10.1111/ejn.13231     Document Type: Erratum

References (249)

1. Agarwal, N., Pacher, P., Tegeder, I., Amaya, F., Constantin, C.E., Brenner, G.J., Rubino, T., Michalski, C.W., Marsicano, G., Monory, K., Mackie, K., Marian, C., Batkai, S., Parolaro, D., Fischer, M.J., Reeh, P., Kunos, G., Kress, M., Lutz, B., Woolf, C.J. & Kuner, R. (2007) Cannabinoids mediate analgesia largely via peripheral type 1 cannabinoid receptors in nociceptors. Nat. Neurosci., 10, 870-879.
2. Ahn, K., Johnson, D.S., Mileni, M., Beidler, D., Long, J.Z., McKinney, M.K., Weerapana, E., Sadagopan, N., Liimatta, M., Smith, S.E., Lazerwith, S., Stiff, C., Kamtekar, S., Bhattacharya, K., Zhang, Y., Swaney, S., Van Becelaere, K., Stevens, R.C. & Cravatt, B.F. (2009) Discovery and characterization of a highly selective FAAH inhibitor that reduces inflammatory pain. Chem. Biol., 16, 411-420.
3. Ahn, K., Smith, S.E., Liimatta, M.B., Beidler, D., Sadagopan, N., Dudley, D.T., Young, T., Wren, P., Zhang, Y., Swaney, S., Van Becelaere, K., Blankman, J.L., Nomura, D.K., Bhattachar, S.N., Stiff, C., Nomanbhoy, T.K., Weerapana, E., Johnson, D.S. & Cravatt, B.F. (2011) Mechanistic and pharmacological characterization of PF-04457845: a highly potent and selective fatty acid amide hydrolase inhibitor that reduces inflammatory and noninflammatory pain. J. Pharmacol. Exp. Ther., 338, 114-124.
4. Akil, H., Young, E., Walker, J.M. & Watson, S.J. (1986) The many possible roles of opioids and related peptides in stress-induced analgesia. Ann. NY Acad. Sci., 467, 140-153.
5. Albutaihi, I.A., DeJongste, M.J. & Ter Horst, G.J. (2004) An integrated study of heart pain and behavior in freely moving rats (using for as a marker for neuronal activation). Neurosignals, 13, 207-226.
6. Alexander, J.P. & Cravatt, B.F. (2006) The putative endocannabinoid transport blocker LY2183240 is a potent inhibitor of FAAH and several other brain serine hydrolases. J. Am. Chem. Soc., 128, 9699-9704.
7. Alvarez-Jaimes, L.J. & Palmer, J.A. (2011) The role of endocannabinoids in pain modulation and the therapeutic potential of inhibiting their enzymatic degradation. Curr. Pharm. Biotechno., 12, 1644-1659.
8. Amit, Z. & Galina, Z.H. (1986) Stress-induced analgesia: adaptive pain suppression. Physiol. Rev., 66, 1091-1120.
9. Atwood, B.K. & Mackie, K. (2010) CB2: a cannabinoid receptor with an identity crisis. Brit. J. Pharmacol., 160, 467-479.
10. Azhdari Zarmehri, H., Semnanian, S., Fathollahi, Y., Erami, E., Khakpay, R., Azizi, H. & Rohampour, K. (2011) Intra-periaqueductal gray matter microinjection of orexin-A decreases formalin-induced nociceptive behaviors in adult male rats. J. Pain, 12, 280-287.
11. Bandler, R. & Shipley, M.T. (1994) Columnar organization in the midbrain periaqueductal gray: modules for emotional expression? Trends Neurosci., 17, 379-389.
12. Beaulieu, P., Bisogno, T., Punwar, S., Farquhar-Smith, W.P., Ambrosino, G., Di Marzo, V. & Rice, A.S. (2000) Role of the endogenous cannabinoid system in the formalin test of persistent pain in the rat. Eur. J. Pharmacol., 396, 85-92.
13. Beltramo, M., Stella, N., Calignano, A., Lin, S.Y., Makriyannis, A. & Piomelli, D. (1997) Functional role of high-affinity anandamide transport, as revealed by selective inhibition. Science, 277, 1094-1097.
14. Benedetti, F., Thoen, W., Blanchard, C., Vighetti, S. & Arduino, C. (2013) Pain as a reward: changing the meaning of pain from negative to positive co-activates opioid and cannabinoid systems. Pain, 154, 361-367.
15. Bequet, F., Uzabiaga, F., Desbazeille, M., Ludwiczak, P., Maftouh, M., Picard, C., Scatton, B. & Le Fur, G. (2007) CB1 receptor-mediated control of the release of endocannabinoids (as assessed by microdialysis coupled with LC/MS) in the rat hypothalamus. Eur. J. Neurosci., 26, 3458-3464.
16. Berquin, P., Bodineau, L., Gros, F. & Larnicol, N. (2000) Brainstem and hypothalamic areas involved in respiratory chemoreflexes: a Fos study in adult rats. Brain Res., 857, 30-40.
17. Bisogno, T., Howell, F., Williams, G., Minassi, A., Cascio, M.G., Ligresti, A., Matias, I., Schiano-Moriello, A., Paul, P., Williams, E.J., Gangadharan, U., Hobbs, C., Di Marzo, V. & Doherty, P. (2003) Cloning of the first sn1-DAG lipases points to the spatial and temporal regulation of endocannabinoid signaling in the brain. J. Cell Biol., 163, 463-468.
18. Blankman, J.L., Simon, G.M. & Cravatt, B.F. (2007) A comprehensive profile of brain enzymes that hydrolyze the endocannabinoid 2-arachidonoylglycerol. Chem. Biol., 14, 1347-1356.
19. Bloom, A.S., Dewey, W.L., Harris, L.S. & Brosius, K.K. (1977) 9-nor-9beta-hydroxyhexahydrocannabinol, a cannabinoid with potent antinociceptive activity: comparisons with morphine. J. Pharmacol. Exp. Ther., 200, 263-270.
20. Booker, L., Kinsey, S.G., Abdullah, R.A., Blankman, J.L., Long, J.Z., Ezzili, C., Boger, D.L., Cravatt, B.F. & Lichtman, A.H. (2012) The fatty acid amide hydrolase (FAAH) inhibitor PF-3845 acts in the nervous system to reverse LPS-induced tactile allodynia in mice. Brit. J. Pharmacol., 165, 2485-2496.
21. Busquets-Garcia, A., Puighermanal, E., Pastor, A., de la Torre, R., Maldonado, R. & Ozaita, A. (2011) Differential role of anandamide and 2-arachidonoylglycerol in memory and anxiety-like responses. Biol. Psychiat., 70, 479-486.
22. Butler, R.K., Ford, G.K., Hogan, M., Roche, M., Doyle, K.M., Kelly, J.P., Kendall, D.A., Chapman, V. & Finn, D.P. (2012) Fear-induced suppression of nociceptive behaviour and activation of Akt signalling in the rat periaqueductal grey: role of fatty acid amide hydrolase. J. Psychopharmacol., 26, 83-91.
23. Caille, S., Alvarez-Jaimes, L., Polis, I., Stouffer, D.G. & Parsons, L.H. (2007) Specific alterations of extracellular endocannabinoid levels in the nucleus accumbens by ethanol, heroin, and cocaine self-administration. J. Neurosci., 27, 3695-3702.
24. Calignano, A., La Rana, G., Giuffrida, A. & Piomelli, D. (1998) Control of pain initiation by endogenous cannabinoids. Nature, 394, 277-281.
25. Chanda, P.K., Gao, Y., Mark, L., Btesh, J., Strassle, B.W., Lu, P., Piesla, M.J., Zhang, M.Y., Bingham, B., Uveges, A., Kowal, D., Garbe, D., Kouranova, E.V., Ring, R.H., Bates, B., Pangalos, M.N., Kennedy, J.D., Whiteside, G.T. & Samad, T.A. (2010) Monoacylglycerol lipase activity is a critical modulator of the tone and integrity of the endocannabinoid system. Mol. Pharmacol., 78, 996-1003.
26. Chapman, V. (1999) The cannabinoid CB1 receptor antagonist, SR141716A, selectively facilitates nociceptive responses of dorsal horn neurones in the rat. Brit. J. Pharmacol., 127, 1765-1767.
27. Chen, X.H., Geller, E.B. & Adler, M.W. (1998) CCK(B) receptors in the periaqueductal grey are involved in electroacupuncture antinociception in the rat cold water tail-flick test. Neuropharmacology, 37, 751-757.
28. Chiou, L.C., Lee, H.J., Ho, Y.C., Chen, S.P., Liao, Y.Y., Ma, C.H., Fan, P.C., Fuh, J.L. & Wang, S.J. (2010a) Orexins/hypocretins: pain regulation and cellular actions. Curr. Pharm. Design, 16, 3089-3100.
29. Chiou, L.C., Teng, S.F. & Chang, L.Y. (2010b) Restraint stress induces analgesia through endogenous orexins via OX1 receptor-mediated endocannabinoid retrograde disinhibition in the ventrolateral periaqueductal gray. In Neuroscience 2010, Prog. No. 844.1. San Diego, USA.
30. Clayton, N., Marshall, F.H., Bountra, C. & O'Shaughnessy, C.T. (2002) CB1 and CB2 cannabinoid receptors are implicated in inflammatory pain. Pain, 96, 253-260.
31. Conn, P.J. & Pin, J.P. (1997) Pharmacology and functions of metabotropic glutamate receptors. Annu. Rev. Pharmacol., 37, 205-237.
32. Costa, B. & Colleoni, M. (1999) SR141716A induces in rats a behavioral pattern opposite to that of CB1 receptor agonists. Zhongguo Yao Li Xue Bao, 20, 1103-1108.
33. Cravatt, B.F. & Lichtman, A.H. (2004) The endogenous cannabinoid system and its role in nociceptive behavior. J. Neurobiol., 61, 149-160.
34. Cravatt, B.F., Demarest, K., Patricelli, M.P., Bracey, M.H., Giang, D.K., Martin, B.R. & Lichtman, A.H. (2001) Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proc. Natl. Acad. Sci. USA, 98, 9371-9376.
35. Cravatt, B.F., Saghatelian, A., Hawkins, E.G., Clement, A.B., Bracey, M.H. & Lichtman, A.H. (2004) Functional disassociation of the central and peripheral fatty acid amide signaling systems. Proc. Natl. Acad. Sci. USA, 101, 10821-10826.
36. D'Amico, M., Berrino, L., Maione, S., Filippelli, A., de Novellis, V. & Rossi, F. (1996) Endothelin-1 in periaqueductal gray area of mice induces analgesia via glutamatergic receptors. Pain, 65, 205-209.
37. De Petrocellis, L., Bisogno, T., Maccarrone, M., Davis, J.B., Finazzi-Agro, A. & Di Marzo, V. (2001) The activity of anandamide at vanilloid VR1 receptors requires facilitated transport across the cell membrane and is limited by intracellular metabolism. J. Biol. Chem., 276, 12856-12863.
38. Depaulis, A., Morgan, M.M. & Liebeskind, J.C. (1987) GABAergic modulation of the analgesic effects of morphine microinjected in the ventral periaqueductal gray matter of the rat. Brain Res., 436, 223-228.
39. Desroches, J., Guindon, J., Lambert, C. & Beaulieu, P. (2008) Modulation of the anti-nociceptive effects of 2-arachidonoyl glycerol by peripherally administered FAAH and MGL inhibitors in a neuropathic pain model. Brit. J. Pharmacol., 155, 913-924.
40. Devane, W.A., Hanus, L., Breuer, A., Pertwee, R.G., Stevenson, L.A., Griffin, G., Gibson, D., Mandelbaum, A., Etinger, A. & Mechoulam, R. (1992) Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science, 258, 1946-1949.
41. Di Marzo, V. (2008) Endocannabinoids: synthesis and degradation. Rev. Physiol. Bioch. P., 160, 1-24.
42. Di Marzo, V. (2012) Inhibitors of endocannabinoid breakdown for pain: not so FA(AH)cile, after all. Pain, 153, 1785-1786.
43. Di Marzo, V. & Matias, I. (2005) Endocannabinoid control of food intake and energy balance. Nat. Neurosci., 8, 585-589.
44. Di Marzo, V., Fontana, A., Cadas, H., Schinelli, S., Cimino, G., Schwartz, J.C. & Piomelli, D. (1994) Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature, 372, 686-691.
45. Di Marzo, V., Bisogno, T., Sugiura, T., Melck, D. & De Petrocellis, L. (1998) The novel endogenous cannabinoid 2-arachidonoylglycerol is inactivated by neuronal- and basophil-like cells: connections with anandamide. Biochem. J., 331(Pt 1), 15-19.
46. Di Marzo, V., Bisogno, T. & De Petrocellis, L. (2001) Anandamide: some like it hot. Trends Pharmacol. Sci., 22, 346-349.
47. Di Marzo, V., Bifulco, M. & De Petrocellis, L. (2004) The endocannabinoid system and its therapeutic exploitation. Nat. Rev. Drug Discov., 3, 771-784.
48. Dinh, T.P., Freund, T.F. & Piomelli, D. (2002) A role for monoglyceride lipase in 2-arachidonoylglycerol inactivation. Chem. Phys. Lipids, 121, 149-158.
49. Dinh, T.P., Kathuria, S. & Piomelli, D. (2004) RNA interference suggests a primary role for monoacylglycerol lipase in the degradation of the endocannabinoid 2-arachidonoylglycerol. Mol. Pharmacol., 66, 1260-1264.
50. Dogrul, A., Gardell, L.R., Ma, S., Ossipov, M.H., Porreca, F. & Lai, J. (2002) 'Knock-down' of spinal CB1 receptors produces abnormal pain and elevates spinal dynorphin content in mice. Pain, 100, 203-209.
51. Drew, G.M. & Vaughan, C.W. (2004) Multiple metabotropic glutamate receptor subtypes modulate GABAergic neurotransmission in rat periaqueductal grey neurons in vitro. Neuropharmacology, 46, 927-934.
52. Drew, G.M., Mitchell, V.A. & Vaughan, C.W. (2008) Glutamate spillover modulates GABAergic synaptic transmission in the rat midbrain periaqueductal grey via metabotropic glutamate receptors and endocannabinoid signaling. J. Neurosci., 28, 808-815.
53. Drew, G.M., Lau, B.K. & Vaughan, C.W. (2009) Substance P drives endocannabinoid-mediated disinhibition in a midbrain descending analgesic pathway. J. Neurosci., 29, 7220-7229.
54. Egertova, M., Giang, D.K., Cravatt, B.F. & Elphick, M.R. (1998) A new perspective on cannabinoid signalling: complementary localization of fatty acid amide hydrolase and the CB1 receptor in rat brain. Proc. Biol. Sci., 265, 2081-2085.
55. Egertova, M., Cravatt, B.F. & Elphick, M.R. (2003) Comparative analysis of fatty acid amide hydrolase and cb(1) cannabinoid receptor expression in the mouse brain: evidence of a widespread role for fatty acid amide hydrolase in regulation of endocannabinoid signaling. Neuroscience, 119, 481-496.
56. Egertova, M., Michael, G.J., Cravatt, B.F. & Elphick, M.R. (2004) Fatty acid amide hydrolase in brain ventricular epithelium: mutually exclusive patterns of expression in mouse and rat. J. Chem. Neuroanat., 28, 171-181.
57. Farrant, M. & Nusser, Z. (2005) Variations on an inhibitory theme: phasic and tonic activation of GABA(A) receptors. Nat. Rev. Neurosci., 6, 215-229.
58. Filaretov, A.A., Bogdanov, A.I. & Yarushkina, N.I. (1996) Stress-induced analgesia. The role of hormones produced by the hypophyseal-adrenocortical system. Neurosci. Behav. Physiol., 26, 572-578.
59. Finn, D.P., Beckett, S.R., Richardson, D., Kendall, D.A., Marsden, C.A. & Chapman, V. (2004) Evidence for differential modulation of conditioned aversion and fear-conditioned analgesia by CB1 receptors. Eur. J. Neurosci., 20, 848-852.
60. Flor, H., Birbaumer, N., Schulz, R., Grusser, S.M. & Mucha, R.F. (2002) Pavlovian conditioning of opioid and nonopioid pain inhibitory mechanisms in humans. Eur. J. Pain, 6, 395-402.
61. Fowler, C.J. (2013) Transport of endocannabinoids across the plasma membrane and within the cell. FEBS J., 280, 1895-1904.
62. Freund, T.F. & Hajos, N. (2003) Excitement reduces inhibition via endocannabinoids. Neuron, 38, 362-365.
63. Galiegue, S., Mary, S., Marchand, J., Dussossoy, D., Carriere, D., Carayon, P., Bouaboula, M., Shire, D., Le Fur, G. & Casellas, P. (1995) Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur. J. Biochem., 232, 54-61.
64. Gao, Y., Vasilyev, D.V., Goncalves, M.B., Howell, F.V., Hobbs, C., Reisenberg, M., Shen, R., Zhang, M.Y., Strassle, B.W., Lu, P., Mark, L., Piesla, M.J., Deng, K., Kouranova, E.V., Ring, R.H., Whiteside, G.T., Bates, B., Walsh, F.S., Williams, G., Pangalos, M.N., Samad, T.A. & Doherty, P. (2010) Loss of retrograde endocannabinoid signaling and reduced adult neurogenesis in diacylglycerol lipase knock-out mice. J. Neurosci., 30, 2017-2024.
65. Gaoni, Y. & Mechoulam, R. (1964) Isolation, structure and partial synthesis of an active constituent of hashish. J. Am. Chem. Soc., 86, 1646-1647.
66. Gerard, C.M., Mollereau, C., Vassart, G. & Parmentier, M. (1991) Molecular cloning of a human cannabinoid receptor which is also expressed in testis. Biochem. J., 279(Pt 1), 129-134.
67. Gertsch, J., Leonti, M., Raduner, S., Racz, I., Chen, J.Z., Xie, X.Q., Altmann, K.H., Karsak, M. & Zimmer, A. (2008) Beta-caryophyllene is a dietary cannabinoid. Proc. Natl. Acad. Sci. USA, 105, 9099-9104.
68. Ghosh, S., Wise, L.E., Chen, Y., Gujjar, R., Mahadevan, A., Cravatt, B.F. & Lichtman, A.H. (2013) The monoacylglycerol lipase inhibitor JZL184 suppresses inflammatory pain in the mouse carrageenan model. Life Sci., 92, 498-505.
69. Glaser, S.T., Kaczocha, M. & Deutsch, D.G. (2005) Anandamide transport: a critical review. Life Sci., 77, 1584-1604.
70. Gonsiorek, W., Lunn, C., Fan, X., Narula, S., Lundell, D. & Hipkin, R.W. (2000) Endocannabinoid 2-arachidonyl glycerol is a full agonist through human type 2 cannabinoid receptor: antagonism by anandamide. Mol. Pharmacol., 57, 1045-1050.
71. Goparaju, S.K., Ueda, N., Taniguchi, K. & Yamamoto, S. (1999) Enzymes of porcine brain hydrolyzing 2-arachidonoylglycerol, an endogenous ligand of cannabinoid receptors. Biochem. Pharmacol., 57, 417-423.
72. Greenbaum, L., Tegeder, I., Barhum, Y., Melamed, E., Roditi, Y. & Djaldetti, R. (2012) Contribution of genetic variants to pain susceptibility in Parkinson disease. Eur. J. Pain, 16, 1243-1250.
73. Gregg, L.C., Jung, K.M., Spradley, J.M., Nyilas, R., Suplita, R.L. II., Zimmer, A., Watanabe, M., Mackie, K., Katona, I., Piomelli, D. & Hohmann, A.G. (2012) Activation of type 5 metabotropic glutamate receptors and diacylglycerol lipase-alpha initiates 2-arachidonoylglycerol formation and endocannabinoid-mediated analgesia. J. Neurosci., 32, 9457-9468.
74. Gui, X., Carraway, R.E. & Dobner, P.R. (2004) Endogenous neurotensin facilitates visceral nociception and is required for stress-induced antinociception in mice and rats. Neuroscience, 126, 1023-1032.
75. Guimaraes, A.P., Guimaraes, F.S. & Prado, W.A. (2000) Modulation of carbachol-induced antinociception from the rat periaqueductal gray. Brain Res. Bull., 51, 471-478.
76. Guindon, J., Guijarro, A., Piomelli, D. & Hohmann, A.G. (2011) Peripheral antinociceptive effects of inhibitors of monoacylglycerol lipase in a rat model of inflammatory pain. Brit. J. Pharmacol., 163, 1464-1478.
77. Guindon, J., Lai, Y., Takacs, S.M., Bradshaw, H.B. & Hohmann, A.G. (2013) Alterations in endocannabinoid tone following chemotherapy-induced peripheral neuropathy: effects of endocannabinoid deactivation inhibitors targeting fatty-acid amide hydrolase and monoacylglycerol lipase in comparison to reference analgesics following cisplatin treatment. Pharmacol. Res., 67, 94-109.
78. Gyombolai, P., Pap, D., Turu, G., Catt, K.J., Bagdy, G. & Hunyady, L. (2012) Regulation of endocannabinoid release by G proteins: a paracrine mechanism of G protein-coupled receptor action. Mol. Cell. Endocrinol., 353, 29-36.
79. Haj-Dahmane, S. & Shen, R.Y. (2005) The wake-promoting peptide orexin-B inhibits glutamatergic transmission to dorsal raphe nucleus serotonin neurons through retrograde endocannabinoid signaling. J. Neurosci., 25, 896-905.
80. Haller, V.L., Stevens, D.L. & Welch, S.P. (2008) Modulation of opioids via protection of anandamide degradation by fatty acid amide hydrolase. Eur. J. Pharmacol., 600, 50-58.
81. Hanus, L., Abu-Lafi, S., Fride, E., Breuer, A., Vogel, Z., Shalev, D.E., Kustanovich, I. & Mechoulam, R. (2001) 2-arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor. Proc. Natl. Acad. Sci. USA, 98, 3662-3665.
82. Hasanein, P., Shahidi, S., Komaki, A. & Mirazi, N. (2008) Effects of URB597 as an inhibitor of fatty acid amide hydrolase on modulation of nociception in a rat model of cholestasis. Eur. J. Pharmacol., 591, 132-135.
83. (2+) dependency for triggering retrograde endocannabinoid signal. Neuron, 45, 257-268.
84. (2+) -assisted receptor-driven endocannabinoid release: mechanisms that associate presynaptic and postsynaptic activities. Curr. Opin. Neurobiol., 17, 360-365.
85. Heinricher, M.M., Tavares, I., Leith, J.L. & Lumb, B.M. (2009) Descending control of nociception: specificity, recruitment and plasticity. Brain Res. Rev., 60, 214-225.
86. Herkenham, M., Lynn, A.B., Johnson, M.R., Melvin, L.S., de Costa, B.R. & Rice, K.C. (1991) Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J. Neurosci., 11, 563-583.
87. Ho, Y.C., Lee, H.J., Tung, L.W., Liao, Y.Y., Fu, S.Y., Teng, S.F., Liao, H.T., Mackie, K. & Chiou, L.C. (2011) Activation of orexin 1 receptors in the periaqueductal gray of male rats leads to antinociception via retrograde endocannabinoid (2-arachidonoylglycerol)-induced disinhibition. J. Neurosci., 31, 14600-14610.
88. Hohmann, A.G., Martin, W.J., Tsou, K. & Walker, J.M. (1995) Inhibition of noxious stimulus-evoked activity of spinal cord dorsal horn neurons by the cannabinoid WIN 55, 212-2. Life Sci., 56, 2111-2118.
89. Hohmann, A.G., Tsou, K. & Walker, J.M. (1999a) Cannabinoid suppression of noxious heat-evoked activity in wide dynamic range neurons in the lumbar dorsal horn of the rat. J. Neurophysiol., 81, 575-583.
90. Hohmann, A.G., Tsou, K. & Walker, J.M. (1999b) Intrathecal cannabinoid administration suppresses noxious stimulus-evoked Fos protein-like immunoreactivity in rat spinal cord: comparison with morphine. Zhongguo Yao Li Xue Bao, 20, 1132-1136.
91. Hohmann, A.G., Suplita, R.L., Bolton, N.M., Neely, M.H., Fegley, D., Mangieri, R., Krey, J.F., Walker, J.M., Holmes, P.V., Crystal, J.D., Duranti, A., Tontini, A., Mor, M., Tarzia, G. & Piomelli, D. (2005) An endocannabinoid mechanism for stress-induced analgesia. Nature, 435, 1108-1112.
92. Holden, J.E., Pizzi, J.A. & Jeong, Y. (2009) An NK1 receptor antagonist microinjected into the periaqueductal gray blocks lateral hypothalamic-induced antinociception in rats. Neurosci. Lett., 453, 115-119.
93. Horvath, T.L., Diano, S. & van den Pol, A.N. (1999a) Synaptic interaction between hypocretin (orexin) and neuropeptide Y cells in the rodent and primate hypothalamus: a novel circuit implicated in metabolic and endocrine regulations. J. Neurosci., 19, 1072-1087.
94. Horvath, T.L., Peyron, C., Diano, S., Ivanov, A., Aston-Jones, G., Kilduff, T.S. & van Den Pol, A.N. (1999b) Hypocretin (orexin) activation and synaptic innervation of the locus coeruleus noradrenergic system. J. Comp. Neurol., 415, 145-159.
95. Howlett, A.C., Barth, F., Bonner, T.I., Cabral, G., Casellas, P., Devane, W.A., Felder, C.C., Herkenham, M., Mackie, K., Martin, B.R., Mechoulam, R. & Pertwee, R.G. (2002) International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol. Rev., 54, 161-202.
96. Howlett, A.C., Breivogel, C.S., Childers, S.R., Deadwyler, S.A., Hampson, R.E. & Porrino, L.J. (2004) Cannabinoid physiology and pharmacology: 30 years of progress. Neuropharmacology, 47(Suppl 1), 345-358.
97. Huang, S.M., Bisogno, T., Trevisani, M., Al-Hayani, A., De Petrocellis, L., Fezza, F., Tognetto, M., Petros, T.J., Krey, J.F., Chu, C.J., Miller, J.D., Davies, S.N., Geppetti, P., Walker, J.M. & Di Marzo, V. (2002) An endogenous capsaicin-like substance with high potency at recombinant and native vanilloid VR1 receptors. Proc. Natl. Acad. Sci. USA, 99, 8400-8405.
98. Huggins, J.P., Smart, T.S., Langman, S., Taylor, L. & Young, T. (2012) An efficient randomised, placebo-controlled clinical trial with the irreversible fatty acid amide hydrolase-1 inhibitor PF-04457845, which modulates endocannabinoids but fails to induce effective analgesia in patients with pain due to osteoarthritis of the knee. Pain, 153, 1837-1846.
99. Ibrahim, M.M., Deng, H., Zvonok, A., Cockayne, D.A., Kwan, J., Mata, H.P., Vanderah, T.W., Lai, J., Porreca, F., Makriyannis, A. & Malan, T.P. Jr. (2003) Activation of CB2 cannabinoid receptors by AM1241 inhibits experimental neuropathic pain: pain inhibition by receptors not present in the CNS. Proc. Natl. Acad. Sci. USA, 100, 10529-10533.
100. Ibrahim, M.M., Rude, M.L., Stagg, N.J., Mata, H.P., Lai, J., Vanderah, T.W., Porreca, F., Buckley, N.E., Makriyannis, A. & Malan, T.P. Jr. (2006) CB(2) cannabinoid receptor mediation of antinociception. Pain, 122, 36-42.
101. Ignatowska-Jankowska, B.M., Ghosh, S., Crowe, M.S., Kinsey, S.G., Niphakis, M.J., Abdullah, R.A., Tao, Q., O'Neal, S.T., Walentiny, D.M., Wiley, J.L., Cravatt, B.F. & Lichtman, A.H. (2013) In vivo characterization of the highly selective monoacylglycerol lipase inhibitor KML29: antinociceptive activity without cannabimimetic side effects. Brit. J. Pharmacol., doi: 10.1111/bph.12298. [Epub ahead of print].
102. Inui, K., Murase, S. & Nosaka, S. (1994) Facilitation of the arterial baroreflex by the ventrolateral part of the midbrain periaqueductal grey matter in rats. J. Physiol., 477(Pt 1), 89-101.
103. Iwamura, H., Suzuki, H., Ueda, Y., Kaya, T. & Inaba, T. (2001) In vitro and in vivo pharmacological characterization of JTE-907, a novel selective ligand for cannabinoid CB2 receptor. J. Pharmacol. Exp. Ther., 296, 420-425.
104. Jarrahian, A., Manna, S., Edgemond, W.S., Campbell, W.B. & Hillard, C.J. (2000) Structure-activity relationships among N-arachidonylethanolamine (Anandamide) head group analogues for the anandamide transporter. J. Neurochem., 74, 2597-2606.
105. Johnson, D.S., Stiff, C., Lazerwith, S.E., Kesten, S.R., Fay, L.K., Morris, M., Beidler, D., Liimatta, M.B., Smith, S.E., Dudley, D.T., Sadagopan, N., Bhattachar, S.N., Kesten, S.J., Nomanbhoy, T.K., Cravatt, B.F. & Ahn, K. (2011) Discovery of PF-04457845: a highly potent, orally bioavailable, and selective urea FAAH inhibitor. ACS Med. Chem. Lett., 2, 91-96.
106. Kalivas, P.W., Jennes, L., Nemeroff, C.B. & Prange, A.J. Jr. (1982) Neurotensin: topographical distribution of brain sites involved in hypothermia and antinociception. J. Comp. Neurol., 210, 225-238.
107. Kano, M., Ohno-Shosaku, T., Hashimotodani, Y., Uchigashima, M. & Watanabe, M. (2009) Endocannabinoid-mediated control of synaptic transmission. Physiol. Rev., 89, 309-380.
108. Kathuria, S., Gaetani, S., Fegley, D., Valino, F., Duranti, A., Tontini, A., Mor, M., Tarzia, G., La Rana, G., Calignano, A., Giustino, A., Tattoli, M., Palmery, M., Cuomo, V. & Piomelli, D. (2003) Modulation of anxiety through blockade of anandamide hydrolysis. Nat. Med., 9, 76-81.
109. Katona, I., Sperlagh, B., Sik, A., Kafalvi, A., Vizi, E.S., Mackie, K. & Freund, T.F. (1999) Presynaptically located CB1 cannabinoid receptors regulate GABA release from axon terminals of specific hippocampal interneurons. J. Neurosci., 19, 4544-4558.
110. Kawahara, H., Drew, G.M., Christie, M.J. & Vaughan, C.W. (2011) Inhibition of fatty acid amide hydrolase unmasks CB1 receptor and TRPV1 channel-mediated modulation of glutamatergic synaptic transmission in midbrain periaqueductal grey. Brit. J. Pharmacol., 163, 1214-1222.
111. Khasabova, I.A., Chandiramani, A., Harding-Rose, C., Simone, D.A. & Seybold, V.S. (2011) Increasing 2-arachidonoyl glycerol signaling in the periphery attenuates mechanical hyperalgesia in a model of bone cancer pain. Pharmacol. Res., 64, 60-67.
112. Kinsey, S.G., Long, J.Z., O'Neal, S.T., Abdullah, R.A., Poklis, J.L., Boger, D.L., Cravatt, B.F. & Lichtman, A.H. (2009) Blockade of endocannabinoid-degrading enzymes attenuates neuropathic pain. J. Pharmacol. Exp. Ther., 330, 902-910.
113. Kinsey, S.G., Long, J.Z., Cravatt, B.F. & Lichtman, A.H. (2010) Fatty acid amide hydrolase and monoacylglycerol lipase inhibitors produce anti-allodynic effects in mice through distinct cannabinoid receptor mechanisms. J. Pain, 11, 1420-1428.
114. Kinsey, S.G., Wise, L.E., Ramesh, D., Abdullah, R., Selley, D.E., Cravatt, B.F. & Lichtman, A.H. (2013) Repeated low-dose administration of the monoacylglycerol lipase inhibitor JZL184 retains cannabinoid receptor type 1-mediated antinociceptive and gastroprotective effects. J. Pharmacol. Exp. Ther., 345, 492-501.
115. Landsman, R.S., Burkey, T.H., Consroe, P., Roeske, W.R. & Yamamura, H.I. (1997) SR141716A is an inverse agonist at the human cannabinoid CB1 receptor. Eur. J. Pharmacol., 334, R1-R2.
116. Lau, B.K. & Vaughan, C.W. (2008) Muscarinic modulation of synaptic transmission via endocannabinoid signalling in the rat midbrain periaqueductal gray. Mol. Pharmacol., 74, 1392-1398.
117. Lauckner, J.E., Hille, B. & Mackie, K. (2005) The cannabinoid agonist WIN55, 212-2 increases intracellular calcium via CB1 receptor coupling to Gq/11 G proteins. Proc. Natl. Acad. Sci. USA, 102, 19144-19149.
118. de Lecea, L., Kilduff, T.S., Peyron, C., Gao, X., Foye, P.E., Danielson, P.E., Fukuhara, C., Battenberg, E.L., Gautvik, V.T., Bartlett, F.S. II., Frankel, W.N., van den Pol, A.N., Bloom, F.E., Gautvik, K.M. & Sutcliffe, J.G. (1998) The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity. Proc. Natl. Acad. Sci. USA, 95, 322-327.
119. Ledent, C., Valverde, O., Cossu, G., Petitet, F., Aubert, J.F., Beslot, F., Bohme, G.A., Imperato, A., Pedrazzini, T., Roques, B.P., Vassart, G., Fratta, W. & Parmentier, M. (1999) Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice. Science, 283, 401-404.
120. Leung, D., Saghatelian, A., Simon, G.M. & Cravatt, B.F. (2006) Inactivation of N-acyl phosphatidylethanolamine phospholipase D reveals multiple mechanisms for the biosynthesis of endocannabinoids. Biochemistry, 45, 4720-4726.
121. Lewis, V.A. & Gebhart, G.F. (1977) Evaluation of the periaqueductal central gray (PAG) as a morphine-specific locus of action and examination of morphine-induced and stimulation-produced analgesia at coincident PAG loci. Brain Res., 124, 283-303.
122. Liao, H.T., Lee, H.J., Ho, Y.C. & Chiou, L.C. (2011) Capsaicin in the periaqueductal gray induces analgesia via metabotropic glutamate receptor-mediated endocannabinoid retrograde disinhibition. Brit. J. Pharmacol., 163, 330-345.
123. Lichtman, A.H., Cook, S.A. & Martin, B.R. (1996) Investigation of brain sites mediating cannabinoid-induced antinociception in rats: evidence supporting periaqueductal gray involvement. J. Pharmacol. Exp. Ther., 276, 585-593.
124. Lichtman, A.H., Hawkins, E.G., Griffin, G. & Cravatt, B.F. (2002) Pharmacological activity of fatty acid amides is regulated, but not mediated, by fatty acid amide hydrolase in vivo. J. Pharmacol. Exp. Ther., 302, 73-79.
125. Lichtman, A.H., Leung, D., Shelton, C.C., Saghatelian, A., Hardouin, C., Boger, D.L. & Cravatt, B.F. (2004a) Reversible inhibitors of fatty acid amide hydrolase that promote analgesia: evidence for an unprecedented combination of potency and selectivity. J. Pharmacol. Exp. Ther., 311, 441-448.
126. Lichtman, A.H., Shelton, C.C., Advani, T. & Cravatt, B.F. (2004b) Mice lacking fatty acid amide hydrolase exhibit a cannabinoid receptor-mediated phenotypic hypoalgesia. Pain, 109, 319-327.
127. Liu, J., Wang, L., Harvey-White, J., Huang, B.X., Kim, H.Y., Luquet, S., Palmiter, R.D., Krystal, G., Rai, R., Mahadevan, A., Razdan, R.K. & Kunos, G. (2008) Multiple pathways involved in the biosynthesis of anandamide. Neuropharmacology, 54, 1-7.
128. Long, J.Z., Nomura, D.K. & Cravatt, B.F. (2009a) Characterization of monoacylglycerol lipase inhibition reveals differences in central and peripheral endocannabinoid metabolism. Chem. Biol., 16, 744-753.
129. Long, J.Z., Nomura, D.K., Vann, R.E., Walentiny, D.M., Booker, L., Jin, X., Burston, J.J., Sim-Selley, L.J., Lichtman, A.H., Wiley, J.L. & Cravatt, B.F. (2009b) Dual blockade of FAAH and MAGL identifies behavioral processes regulated by endocannabinoid crosstalk in vivo. Proc. Natl. Acad. Sci. USA, 106, 20270-20275.
130. Lotsch, J. & Geisslinger, G. (2011) Pharmacogenetics of new analgesics. Brit. J. Pharmacol., 163, 447-460.
131. Mackie, K., Lai, Y., Westenbroek, R. & Mitchell, R. (1995) Cannabinoids activate an inwardly rectifying potassium conductance and inhibit Q-type calcium currents in AtT20 cells transfected with rat brain cannabinoid receptor. J. Neurosci., 15, 6552-6561.
132. Maione, S., Marabese, I., Leyva, J., Palazzo, E., de Novellis, V. & Rossi, F. (1998) Characterisation of mGluRs which modulate nociception in the PAG of the mouse. Neuropharmacology, 37, 1475-1483.
133. Maione, S., Oliva, P., Marabese, I., Palazzo, E., Rossi, F., Berrino, L. & Filippelli, A. (2000) Periaqueductal gray matter metabotropic glutamate receptors modulate formalin-induced nociception. Pain, 85, 183-189.
134. Maione, S., Bisogno, T., de Novellis, V., Palazzo, E., Cristino, L., Valenti, M., Petrosino, S., Guglielmotti, V., Rossi, F. & Di Marzo, V. (2006) Elevation of endocannabinoid levels in the ventrolateral periaqueductal grey through inhibition of fatty acid amide hydrolase affects descending nociceptive pathways via both cannabinoid receptor type 1 and transient receptor potential vanilloid type-1 receptors. J. Pharmacol. Exp. Ther., 316, 969-982.
135. Malan, T.P. Jr., Ibrahim, M.M., Deng, H., Liu, Q., Mata, H.P., Vanderah, T., Porreca, F. & Makriyannis, A. (2001) CB2 cannabinoid receptor-mediated peripheral antinociception. Pain, 93, 239-245.
136. Marabese, I., Rossi, F., Palazzo, E., de Novellis, V., Starowicz, K., Cristino, L., Vita, D., Gatta, L., Guida, F., Di Marzo, V., Rossi, F. & Maione, S. (2007) Periaqueductal gray metabotropic glutamate receptor subtype 7 and 8 mediate opposite effects on amino acid release, rostral ventromedial medulla cell activities, and thermal nociception. J. Neurophysiol., 98, 43-53.
137. Maresz, K., Carrier, E.J., Ponomarev, E.D., Hillard, C.J. & Dittel, B.N. (2005) Modulation of the cannabinoid CB2 receptor in microglial cells in response to inflammatory stimuli. J. Neurochem., 95, 437-445.
138. Marrs, W.R., Blankman, J.L., Horne, E.A., Thomazeau, A., Lin, Y.H., Coy, J., Bodor, A.L., Muccioli, G.G., Hu, S.S., Woodruff, G., Fung, S., Lafourcade, M., Alexander, J.P., Long, J.Z., Li, W., Xu, C., Moller, T., Mackie, K., Manzoni, O.J., Cravatt, B.F. & Stella, N. (2010) The serine hydrolase ABHD6 controls the accumulation and efficacy of 2-AG at cannabinoid receptors. Nat. Neurosci., 13, 951-957.
139. Marsicano, G., Wotjak, C.T., Azad, S.C., Bisogno, T., Rammes, G., Cascio, M.G., Hermann, H., Tang, J., Hofmann, C., Zieglgansberger, W., Di Marzo, V. & Lutz, B. (2002) The endogenous cannabinoid system controls extinction of aversive memories. Nature, 418, 530-534.
140. Martin, W.J., Patrick, S.L., Coffin, P.O., Tsou, K. & Walker, J.M. (1995) An examination of the central sites of action of cannabinoid-induced antinociception in the rat. Life Sci., 56, 2103-2109.
141. Martin, W.J., Hohmann, A.G. & Walker, J.M. (1996) Suppression of noxious stimulus-evoked activity in the ventral posterolateral nucleus of the thalamus by a cannabinoid agonist: correlation between electrophysiological and antinociceptive effects. J. Neurosci., 16, 6601-6611.
142. Matsuda, L.A., Lolait, S.J., Brownstein, M.J., Young, A.C. & Bonner, T.I. (1990) Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature, 346, 561-564.
143. Matyas, F., Urban, G.M., Watanabe, M., Mackie, K., Zimmer, A., Freund, T.F. & Katona, I. (2008) Identification of the sites of 2-arachidonoylglycerol synthesis and action imply retrograde endocannabinoid signaling at both GABAergic and glutamatergic synapses in the ventral tegmental area. Neuropharmacology, 54, 95-107.
144. Mechoulam, R., Ben-Shabat, S., Hanus, L., Ligumsky, M., Kaminski, N.E., Schatz, A.R., Gopher, A., Almog, S., Martin, B.R., Compton, D.R., Pertwee, R.G., Griffin, G., Bayewitch, M., Barg, J. & Vogel, Z. (1995) Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem. Pharmacol., 50, 83-90.
145. Meng, I.D., Manning, B.H., Martin, W.J. & Fields, H.L. (1998) An analgesia circuit activated by cannabinoids. Nature, 395, 381-383.
146. Millan, M.J. (2002) Descending control of pain. Prog. Neurobiol., 66, 355-474.
147. Mitchell, V.A., Kawahara, H. & Vaughan, C.W. (2009) Neurotensin inhibition of GABAergic transmission via mGluR-induced endocannabinoid signalling in rat periaqueductal grey. J. Physiol., 587, 2511-2520.
148. Mitchell, V.A., Jeong, H.J., Drew, G.M. & Vaughan, C.W. (2011) Cholecystokinin exerts an effect via the endocannabinoid system to inhibit GABAergic transmission in midbrain periaqueductal gray. Neuropsychopharmacol., 36, 1801-1810.
149. Monassi, C.R., Hoffmann, A. & Menescal-de-Oliveira, L. (1997) Involvement of the cholinergic system and periaqueductal gray matter in the modulation of tonic immobility in the guinea pig. Physiol. Behav., 62, 53-59.
150. Morgan, M.M., Whitney, P.K. & Gold, M.S. (1998) Immobility and flight associated with antinociception produced by activation of the ventral and lateral/dorsal regions of the rat periaqueductal gray. Brain Res., 804, 159-166.
151. Munro, S., Thomas, K.L. & Abu-Shaar, M. (1993) Molecular characterization of a peripheral receptor for cannabinoids. Nature, 365, 61-65.
152. Nackley, A.G., Makriyannis, A. & Hohmann, A.G. (2003a) Selective activation of cannabinoid CB(2) receptors suppresses spinal fos protein expression and pain behavior in a rat model of inflammation. Neuroscience, 119, 747-757.
153. Nackley, A.G., Suplita, R.L. II. & Hohmann, A.G. (2003b) A peripheral cannabinoid mechanism suppresses spinal fos protein expression and pain behavior in a rat model of inflammation. Neuroscience, 117, 659-670.
154. de Novellis, V., Marabese, I., Palazzo, E., Rossi, F., Berrino, L., Rodella, L., Bianchi, R. & Maione, S. (2003) Group I metabotropic glutamate receptors modulate glutamate and gamma-aminobutyric acid release in the periaqueductal grey of rats. Eur. J. Pharmacol., 462, 73-81.
155. Nusser, Z., Mulvihill, E., Streit, P. & Somogyi, P. (1994) Subsynaptic segregation of metabotropic and ionotropic glutamate receptors as revealed by immunogold localization. Neuroscience, 61, 421-427.
156. Nyilas, R., Dudok, B., Urban, G.M., Mackie, K., Watanabe, M., Cravatt, B.F., Freund, T.F. & Katona, I. (2008) Enzymatic machinery for endocannabinoid biosynthesis associated with calcium stores in glutamatergic axon terminals. J. Neurosci., 28, 1058-1063.
157. Nyilas, R., Gregg, L.C., Mackie, K., Watanabe, M., Zimmer, A., Hohmann, A.G. & Katona, I. (2009) Molecular architecture of endocannabinoid signaling at nociceptive synapses mediating analgesia. Eur. J. Neurosci., 29, 1964-1978.
158. Ohishi, H., Akazawa, C., Shigemoto, R., Nakanishi, S. & Mizuno, N. (1995) Distributions of the mRNAs for L-2-amino-4-phosphonobutyrate-sensitive metabotropic glutamate receptors, mGluR4 and mGluR7, in the rat brain. J. Comp. Neurol., 360, 555-570.
159. Okamoto, Y., Wang, J., Morishita, J. & Ueda, N. (2007) Biosynthetic pathways of the endocannabinoid anandamide. Chem. Biodivers., 4, 1842-1857.
160. Olango, W.M., Roche, M., Ford, G.K., Harhen, B. & Finn, D.P. (2012) The endocannabinoid system in the rat dorsolateral periaqueductal grey mediates fear-conditioned analgesia and controls fear expression in the presence of nociceptive tone. Brit. J. Pharmacol., 165, 2549-2560.
161. Oliva, P., Berrino, L., de Novellis, V., Palazzo, E., Marabese, I., Siniscalco, D., Scafuro, M., Mariani, L., Rossi, F. & Maione, S. (2006) Role of periaqueductal grey prostaglandin receptors in formalin-induced hyperalgesia. Eur. J. Pharmacol., 530, 40-47.
162. Palazzo, E., Marabese, I., de Novellis, V., Oliva, P., Rossi, F., Berrino, L. & Maione, S. (2001) Metabotropic and NMDA glutamate receptors participate in the cannabinoid-induced antinociception. Neuropharmacology, 40, 319-326.
163. Palazzo, E., de Novellis, V., Marabese, I., Cuomo, D., Rossi, F., Berrino, L. & Maione, S. (2002) Interaction between vanilloid and glutamate receptors in the central modulation of nociception. Eur. J. Pharmacol., 439, 69-75.
164. Palazzo, E., Guida, F., Gatta, L., Luongo, L., Boccella, S., Bellini, G., Marabese, I., de Novellis, V., Rossi, F. & Maione, S. (2011) EP1 receptor within the ventrolateral periaqueductal grey controls thermonociception and rostral ventromedial medulla cell activity in healthy and neuropathic rat. Mol. Pain, 7, 82.
165. Pamplona, F.A., Ferreira, J., Menezes de Lima, O. Jr., Duarte, F.S., Bento, A.F., Forner, S., Villarinho, J.G., Bellocchio, L., Wotjak, C.T., Lerner, R., Monory, K., Lutz, B., Canetti, C., Matias, I., Calixto, J.B., Marsicano, G., Guimaraes, M.Z. & Takahashi, R.N. (2012) Anti-inflammatory lipoxin A4 is an endogenous allosteric enhancer of CB1 cannabinoid receptor. Proc. Natl. Acad. Sci. USA, 109, 21134-21139.
166. Panula, P., Kalso, E., Nieminen, M., Kontinen, V.K., Brandt, A. & Pertovaara, A. (1999) Neuropeptide FF and modulation of pain. Brain Res., 848, 191-196.
167. Pecina, M., Martinez-Jauand, M., Hodgkinson, C., Stohler, C.S., Goldman, D. & Zubieta, J.K. (2013) FAAH selectively influences placebo effects. Mol. Psychiatr., doi:10.1038/mp.2013.124. [Epub ahead of print].
168. Peng, Y.L., Zhang, J.N., Chang, M., Li, W., Han, R.W. & Wang, R. (2010) Effects of central neuropeptide S in the mouse formalin test. Peptides, 31, 1878-1883.
169. Pernia-Andrade, A.J., Kato, A., Witschi, R., Nyilas, R., Katona, I., Freund, T.F., Watanabe, M., Filitz, J., Koppert, W., Schuttler, J., Ji, G., Neugebauer, V., Marsicano, G., Lutz, B., Vanegas, H. & Zeilhofer, H.U. (2009) Spinal endocannabinoids and CB1 receptors mediate C-fiber-induced heterosynaptic pain sensitization. Science, 325, 760-764.
170. Pert, A., Moody, T.W., Pert, C.B., Dewald, L.A. & Rivier, J. (1980) Bombesin: receptor distribution in brain and effects on nociception and locomotor activity. Brain Res., 193, 209-220.
171. Pertwee, R.G. (2005) Inverse agonism and neutral antagonism at cannabinoid CB1 receptors. Life Sci., 76, 1307-1324.
172. Pertwee, R.G. (2008a) The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. Brit. J. Pharmacol., 153, 199-215.
173. Pertwee, R.G. (2008b) Ligands that target cannabinoid receptors in the brain: from THC to anandamide and beyond. Addict. Biol., 13, 147-159.
174. Pertwee, R.G. (2012) Lipoxin A4 is an allosteric endocannabinoid that strengthens anandamide-induced CB1 receptor activation. Proc. Natl. Acad. Sci. USA, 109, 20781-20782.
175. Pertwee, R.G. (2013) Elevating endocannabinoid levels: pharmacological strategies and potential therapeutic applications. Proc. Nutr. Soc., 18, 1-10.
176. Pertwee, R.G., Howlett, A.C., Abood, M.E., Alexander, S.P., Di Marzo, V., Elphick, M.R., Greasley, P.J., Hansen, H.S., Kunos, G., Mackie, K., Mechoulam, R. & Ross, R.A. (2010) International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB(1) and CB(2). Pharmacol. Rev., 62, 588-631.
177. Peyron, C., Tighe, D.K., van den Pol, A.N., de Lecea, L., Heller, H.C., Sutcliffe, J.G. & Kilduff, T.S. (1998) Neurons containing hypocretin (orexin) project to multiple neuronal systems. J. Neurosci., 18, 9996-10015.
178. Pin, J.P. & Duvoisin, R. (1995) The metabotropic glutamate receptors: structure and functions. Neuropharmacology, 34, 1-26.
179. Piomelli, D., Giuffrida, A., Calignano, A. & Rodriguez de Fonseca, F. (2000) The endocannabinoid system as a target for therapeutic drugs. Trends Pharmacol. Sci., 21, 218-224.
180. van den Pol, A.N. (1999) Hypothalamic hypocretin (orexin): robust innervation of the spinal cord. J. Neurosci., 19, 3171-3182.
181. Porter, A.C., Sauer, J.M., Knierman, M.D., Becker, G.W., Berna, M.J., Bao, J., Nomikos, G.G., Carter, P., Bymaster, F.P., Leese, A.B. & Felder, C.C. (2002) Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor. J. Pharmacol. Exp. Ther., 301, 1020-1024.
182. Puighermanal, E., Busquets-Garcia, A., Maldonado, R. & Ozaita, A. (2012) Cellular and intracellular mechanisms involved in the cognitive impairment of cannabinoids. Philos. T. Roy. Soc. B., 367, 3254-3263.
183. Racz, I., Nadal, X., Alferink, J., Banos, J.E., Rehnelt, J., Martin, M., Pintado, B., Gutierrez-Adan, A., Sanguino, E., Bellora, N., Manzanares, J., Zimmer, A. & Maldonado, R. (2008a) Interferon-gamma is a critical modulator of CB(2) cannabinoid receptor signaling during neuropathic pain. J. Neurosci., 28, 12136-12145.
184. Racz, I., Nadal, X., Alferink, J., Banos, J.E., Rehnelt, J., Martin, M., Pintado, B., Gutierrez-Adan, A., Sanguino, E., Manzanares, J., Zimmer, A. & Maldonado, R. (2008b) Crucial role of CB(2) cannabinoid receptor in the regulation of central immune responses during neuropathic pain. J. Neurosci., 28, 12125-12135.
185. Reynolds, D.V. (1969) Surgery in the rat during electrical analgesia induced by focal brain stimulation. Science, 164, 444-445.
186. Rhee, M.H., Bayewitch, M., Avidor-Reiss, T., Levy, R. & Vogel, Z. (1998) Cannabinoid receptor activation differentially regulates the various adenylyl cyclase isozymes. J. Neurochem., 71, 1525-1534.
187. Richardson, J.D., Aanonsen, L. & Hargreaves, K.M. (1997) SR 141716A, a cannabinoid receptor antagonist, produces hyperalgesia in untreated mice. Eur. J. Pharmacol., 319, R3-R4.
188. Richardson, J.D., Aanonsen, L. & Hargreaves, K.M. (1998a) Hypoactivity of the spinal cannabinoid system results in NMDA-dependent hyperalgesia. J. Neurosci., 18, 451-457.
189. Richardson, J.D., Kilo, S. & Hargreaves, K.M. (1998b) Cannabinoids reduce hyperalgesia and inflammation via interaction with peripheral CB1 receptors. Pain, 75, 111-119.
190. Riedel, G. (1996) Function of metabotropic glutamate receptors in learning and memory. Trends Neurosci., 19, 219-224.
191. Rinaldi-Carmona, M., Barth, F., Héaulme, M., Shire, D., Calandra, B., Congy, C., Martinez, S., Maruani, J., Néliat, G., Caput, D., Ferrara, P., Soubrié, P., Brelière, J.C. & Le Fur, G. (1994) SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett., 350, 240-244.
192. Rosen, A., Zhang, Y.X., Lund, I., Lundeberg, T. & Yu, L.C. (2004) Substance P microinjected into the periaqueductal gray matter induces antinociception and is released following morphine administration. Brain Res., 1001, 87-94.
193. Ruehle, S., Remmers, F., Romo-Parra, H., Massa, F., Wickert, M., Wortge, S., Haring, M., Kaiser, N., Marsicano, G., Pape, H.C. & Lutz, B. (2013) Cannabinoid CB1 receptor in dorsal telencephalic glutamatergic neurons: distinctive sufficiency for hippocampus-dependent and amygdala-dependent synaptic and behavioral functions. J. Neurosci., 33, 10264-10277.
194. Russo, R., Loverme, J., La Rana, G., Compton, T.R., Parrott, J., Duranti, A., Tontini, A., Mor, M., Tarzia, G., Calignano, A. & Piomelli, D. (2007) The fatty acid amide hydrolase inhibitor URB597 (cyclohexylcarbamic acid 3′-carbamoylbiphenyl-3-yl ester) reduces neuropathic pain after oral administration in mice. J. Pharmacol. Exp. Ther., 322, 236-242.
195. Sakurai, T., Amemiya, A., Ishii, M., Matsuzaki, I., Chemelli, R.M., Tanaka, H., Williams, S.C., Richarson, J.A., Kozlowski, G.P., Wilson, S., Arch, J.R., Buckingham, R.E., Haynes, A.C., Carr, S.A., Annan, R.S., McNulty, D.E., Liu, W.S., Terrett, J.A., Elshourbagy, N.A., Bergsma, D.J. & Yanagisawa, M. (1998) Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell, 92, 573-585.
196. Sasso, O., Bertorelli, R., Bandiera, T., Scarpelli, R., Colombano, G., Armirotti, A., Moreno-Sanz, G., Reggiani, A. & Piomelli, D. (2012) Peripheral FAAH inhibition causes profound antinociception and protects against indomethacin-induced gastric lesions. Pharmacol. Res., 65, 553-563.
197. Savinainen, J.R., Jarvinen, T., Laine, K. & Laitinen, J.T. (2001) Despite substantial degradation, 2-arachidonoylglycerol is a potent full efficacy agonist mediating CB(1) receptor-dependent G-protein activation in rat cerebellar membranes. Brit. J. Pharmacol., 134, 664-672.
198. Schindler, M., Holloway, S., Hathway, G., Woolf, C.J., Humphrey, P.P. & Emson, P.C. (1998) Identification of somatostatin sst2(a) receptor expressing neurones in central regions involved in nociception. Brain Res., 798, 25-35.
199. Schlosburg, J.E., Blankman, J.L., Long, J.Z., Nomura, D.K., Pan, B., Kinsey, S.G., Nguyen, P.T., Ramesh, D., Booker, L., Burston, J.J., Thomas, E.A., Selley, D.E., Sim-Selley, L.J., Liu, Q.S., Lichtman, A.H. & Cravatt, B.F. (2010) Chronic monoacylglycerol lipase blockade causes functional antagonism of the endocannabinoid system. Nat. Neurosci., 13, 1113-1119.
200. Schmid, P.C., Reddy, P.V., Natarajan, V. & Schmid, H.H. (1983) Metabolism of N-acylethanolamine phospholipids by a mammalian phosphodiesterase of the phospholipase D type. J. Biol. Chem., 258, 9302-9306.
201. Scott, C.W., Tian, G., Yu, X.H., Paschetto, K.A., Wilkins, D.E., Meury, L., Cao, C.Q., Varnes, J. & Edwards, P.D. (2011) Biochemical characterization and in vitro activity of AZ513, a noncovalent, reversible, and noncompetitive inhibitor of fatty acid amide hydrolase. Eur. J. Pharmacol., 667, 74-79.
202. Serrano, A. & Parsons, L.H. (2011) Endocannabinoid influence in drug reinforcement, dependence and addiction-related behaviors. Pharmacol. Therapeut., 132, 215-241.
203. Shen, M., Piser, T.M., Seybold, V.S. & Thayer, S.A. (1996) Cannabinoid receptor agonists inhibit glutamatergic synaptic transmission in rat hippocampal cultures. J. Neurosci., 16, 4322-4334.
204. Sigel, E., Baur, R., Racz, I., Marazzi, J., Smart, T.G., Zimmer, A. & Gertsch, J. (2011) The major central endocannabinoid directly acts at GABA(A) receptors. Proc. Natl. Acad. Sci. USA, 108, 18150-18155.
205. Simon, G.M. & Cravatt, B.F. (2006) Endocannabinoid biosynthesis proceeding through Glycerophospho-N-Acyl ethanolamine and a role for alpha/beta hydrolase 4 in this pathway. J. Biol. Chem., 281, 26465-26472.
206. Simon, G.M. & Cravatt, B.F. (2010) Characterization of mice lacking candidate N-acyl ethanolamine biosynthetic enzymes provides evidence for multiple pathways that contribute to endocannabinoid production in vivo. Mol. BioSyst., 6, 1411-1418.
207. Sink, K.S., McLaughlin, P.J., Wood, J.A., Brown, C., Fan, P., Vemuri, V.K., Peng, Y., Olszewska, T., Thakur, G.A., Makriyannis, A., Parker, L.A. & Salamone, J.D. (2008) The novel cannabinoid CB1 receptor neutral antagonist AM4113 suppresses food intake and food-reinforced behavior but does not induce signs of nausea in rats. Neuropsychopharmacol., 33, 946-955.
208. Sipe, J.C., Chiang, K., Gerber, A.L., Beutler, E. & Cravatt, B.F. (2002) A missense mutation in human fatty acid amide hydrolase associated with problem drug use. Proc. Natl. Acad. Sci. USA, 99, 8394-8399.
209. Sit, S. & Xie, K. (2002) Bisarylimidazolyl fatty acid amide hydrolase inhibitors. Available online http://patents.justia.com/patent/20020188009.
210. Sit, S. & Xie, K. (2003) (Oxime) carbamoyl fatty acid amide hydrolase inhibitors. Available online http://patentscope.wipo.int/search/en/WO2003065989.
211. Starowicz, K., Maione, S., Cristino, L., Palazzo, E., Marabese, I., Rossi, F., de Novellis, V. & Di Marzo, V. (2007) Tonic endovanilloid facilitation of glutamate release in brainstem descending antinociceptive pathways. J. Neurosci., 27, 13739-13749.
212. Strangman, N.M., Patrick, S.L., Hohmann, A.G., Tsou, K. & Walker, J.M. (1998) Evidence for a role of endogenous cannabinoids in the modulation of acute and tonic pain sensitivity. Brain Res., 813, 323-328.
213. Sugiura, T., Kondo, S., Sukagawa, A., Nakane, S., Shinoda, A., Itoh, K., Yamashita, A. & Waku, K. (1995) 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem. Bioph. Res. Co., 215, 89-97.
214. Sugiura, T., Kondo, S., Kishimoto, S., Miyashita, T., Nakane, S., Kodaka, T., Suhara, Y., Takayama, H. & Waku, K. (2000) Evidence that 2-arachidonoylglycerol but not N-palmitoylethanolamine or anandamide is the physiological ligand for the cannabinoid CB2 receptor. Comparison of the agonistic activities of various cannabinoid receptor ligands in HL-60 cells. J. Biol. Chem., 275, 605-612.
215. Sugiura, T., Kobayashi, Y., Oka, S. & Waku, K. (2002) Biosynthesis and degradation of anandamide and 2-arachidonoylglycerol and their possible physiological significance. Prostag. Leukotr. Ess., 66, 173-192.
216. Sun, Y.X., Tsuboi, K., Okamoto, Y., Tonai, T., Murakami, M., Kudo, I. & Ueda, N. (2004) Biosynthesis of anandamide and N-palmitoylethanolamine by sequential actions of phospholipase A2 and lysophospholipase D. Biochem. J., 380, 749-756.
217. Tallent, M., Liapakis, G., O'Carroll, A.M., Lolait, S.J., Dichter, M. & Reisine, T. (1996) Somatostatin receptor subtypes SSTR2 and SSTR5 couple negatively to an L-type Ca2+ current in the pituitary cell line AtT-20. Neuroscience, 71, 1073-1081.
218. Tamaru, Y., Nomura, S., Mizuno, N. & Shigemoto, R. (2001) Distribution of metabotropic glutamate receptor mGluR3 in the mouse CNS: differential location relative to pre- and postsynaptic sites. Neuroscience, 106, 481-503.
219. Thoburn, K.K., Hough, L.B., Nalwalk, J.W. & Mischler, S.A. (1994) Histamine-induced modulation of nociceptive responses. Pain, 58, 29-37.
220. Tsou, K., Lowitz, K.A., Hohmann, A.G., Martin, W.J., Hathaway, C.B., Bereiter, D.A. & Walker, J.M. (1996) Suppression of noxious stimulus-evoked expression of Fos protein-like immunoreactivity in rat spinal cord by a selective cannabinoid agonist. Neuroscience, 70, 791-798.
221. Tsou, K., Brown, S., Sanudo-Pena, M.C., Mackie, K. & Walker, J.M. (1998a) Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system. Neuroscience, 83, 393-411.
222. Tsou, K., Nogueron, M.I., Muthian, S., Sanudo-Pena, M.C., Hillard, C.J., Deutsch, D.G. & Walker, J.M. (1998b) Fatty acid amide hydrolase is located preferentially in large neurons in the rat central nervous system as revealed by immunohistochemistry. Neurosci. Lett., 254, 137-140.
223. Tsujino, N. & Sakurai, T. (2009) Orexin/hypocretin: a neuropeptide at the interface of sleep, energy homeostasis, and reward system. Pharmacol. Rev., 61, 162-176.
224. Turu, G., Varnai, P., Gyombolai, P., Szidonya, L., Offertaler, L., Bagdy, G., Kunos, G. & Hunyady, L. (2009) Paracrine transactivation of the CB1 cannabinoid receptor by AT1 angiotensin and other Gq/11 protein-coupled receptors. J. Biol. Chem., 284, 16914-16921.
225. Valverde, O., Ledent, C., Beslot, F., Parmentier, M. & Roques, B.P. (2000) Reduction of stress-induced analgesia but not of exogenous opioid effects in mice lacking CB1 receptors. Eur. J. Neurosci., 12, 533-539.
226. Van Sickle, M.D., Duncan, M., Kingsley, P.J., Mouihate, A., Urbani, P., Mackie, K., Stella, N., Makriyannis, A., Piomelli, D., Davison, J.S., Marnett, L.J., Di Marzo, V., Pittman, Q.J., Patel, K.D. & Sharkey, K.A. (2005) Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science, 310, 329-332.
227. Vandevoorde, S. & Fowler, C.J. (2005) Inhibition of fatty acid amide hydrolase and monoacylglycerol lipase by the anandamide uptake inhibitor VDM11: evidence that VDM11 acts as an FAAH substrate. Brit. J. Pharmacol., 145, 885-893.
228. Vaughan, C.W., Connor, M., Bagley, E.E. & Christie, M.J. (2000) Actions of cannabinoids on membrane properties and synaptic transmission in rat periaqueductal gray neurons in vitro. Mol. Pharmacol., 57, 288-295.
229. Walczak, J.S., Pichette, V., Leblond, F., Desbiens, K. & Beaulieu, P. (2006) Characterization of chronic constriction of the saphenous nerve, a model of neuropathic pain in mice showing rapid molecular and electrophysiological changes. J. Neurosci. Res., 83, 1310-1322.
230. Walker, J.M., Strangman, N.M. & Huang, S.M. (2001) Cannabinoids and pain. Pain Res. Manag., 6, 74-79.
231. Walter, L., Franklin, A., Witting, A., Moller, T. & Stella, N. (2002) Astrocytes in culture produce anandamide and other acylethanolamides. J. Biol. Chem., 277, 20869-20876.
232. Wang, J.Z., Lundeberg, T. & Yu, L. (2000) Antinociceptive effects induced by intra-periaqueductal grey administration of neuropeptide Y in rats. Brain Res., 859, 361-363.
233. Wang, J.Z., Lundeberg, T. & Yu, L.C. (2001) Anti-nociceptive effect of neuropeptide Y in periaqueductal grey in rats with inflammation. Brain Res., 893, 264-267.
234. Watanabe, S., Kuwaki, T., Yanagisawa, M., Fukuda, Y. & Shimoyama, M. (2005) Persistent pain and stress activate pain-inhibitory orexin pathways. NeuroReport, 16, 5-8.
235. Wei, H., Panula, P. & Pertovaara, A. (1998) A differential modulation of allodynia, hyperalgesia and nociception by neuropeptide FF in the periaqueductal gray of neuropathic rats: interactions with morphine and naloxone. Neuroscience, 86, 311-319.
236. Wei, B.Q., Mikkelsen, T.S., McKinney, M.K., Lander, E.S. & Cravatt, B.F. (2006) A second fatty acid amide hydrolase with variable distribution among placental mammals. J. Biol. Chem., 281, 36569-36578.
237. Whiteside, G.T., Gottshall, S.L., Boulet, J.M., Chaffer, S.M., Harrison, J.E., Pearson, M.S., Turchin, P.I., Mark, L., Garrison, A.E. & Valenzano, K.J. (2005) A role for cannabinoid receptors, but not endogenous opioids, in the antinociceptive activity of the CB2-selective agonist, GW405833. Eur. J. Pharmacol., 528, 65-72.
238. Wilson-Poe, A.R., Mitchell, V.A. & Vaughan, C.W. (2013) Postsynaptic mGluR mediated excitation of neurons in midbrain periaqueductal grey. Neuropharmacology, 66, 348-354.
239. Woodhams, S.G., Wong, A., Barrett, D.A., Bennett, A.J., Chapman, V. & Alexander, S.P. (2012) Spinal administration of the monoacylglycerol lipase inhibitor JZL184 produces robust inhibitory effects on nociceptive processing and the development of central sensitization in the rat. Brit. J. Pharmacol., 167, 1609-1619.
240. Woolf, N.J., Harrison, J.B. & Buchwald, J.S. (1990) Cholinergic neurons of the feline pontomesencephalon. II. Ascending anatomical projections. Brain Res., 520, 55-72.
241. Wotherspoon, G., Fox, A., McIntyre, P., Colley, S., Bevan, S. & Winter, J. (2005) Peripheral nerve injury induces cannabinoid receptor 2 protein expression in rat sensory neurons. Neuroscience, 135, 235-245.
242. Xiao, Z., Ou, S., He, W.J., Zhao, Y.D., Liu, X.H. & Ruan, H.Z. (2010) Role of midbrain periaqueductal gray P2X3 receptors in electroacupuncture-mediated endogenous pain modulatory systems. Brain Res., 1330, 31-44.
243. Xie, X., Wisor, J.P., Hara, J., Crowder, T.L., LeWinter, R., Khroyan, T.V., Yamanaka, A., Diano, S., Horvath, T.L., Sakurai, T., Toll, L. & Kilduff, T.S. (2008) Hypocretin/orexin and nociceptin/orphanin FQ coordinately regulate analgesia in a mouse model of stress-induced analgesia. J. Clin. Invest., 118, 2471-2481.
244. Xing, J. & Li, J. (2007) TRPV1 receptor mediates glutamatergic synaptic input to dorsolateral periaqueductal gray (dl-PAG) neurons. J. Neurophysiol., 97, 503-511.
245. Xing, J., Lu, J. & Li, J. (2008) Purinergic P2X receptors presynaptically increase glutamatergic synaptic transmission in dorsolateral periaqueductal gray. Brain Res., 1208, 46-55.
246. Yang, J., Li, P., Liang, J.Y., Pan, Y.J., Yan, X.Q., Yan, F.L., Hao, F., Zhang, X.Y., Zhang, J., Qiu, P.Y. & Wang, D.X. (2011) Oxytocin in the periaqueductal grey regulates nociception in the rat. Regul. Peptides, 169, 39-42.
247. Zhang, J., Hoffert, C., Vu, H.K., Groblewski, T., Ahmad, S. & O'Donnell, D. (2003) Induction of CB2 receptor expression in the rat spinal cord of neuropathic but not inflammatory chronic pain models. Eur. J. Neurosci., 17, 2750-2754.
248. Zimmer, A., Zimmer, A.M., Hohmann, A.G., Herkenham, M. & Bonner, T.I. (1999) Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice. Proc. Natl. Acad. Sci. USA, 96, 5780-5785.
249. Zygmunt, P.M., Petersson, J., Andersson, D.A., Chuang, H., Sorgard, M., Di Marzo, V., Julius, D. & Hogestatt, E.D. (1999) Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature, 400, 452-457.